These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 19429730)
1. Patients' survival expectations before localized prostate cancer treatment by treatment status. Mohan R; Beydoun H; Barnes-Ely ML; Lee L; Davis JW; Lance R; Schellhammer P J Am Board Fam Med; 2009; 22(3):247-56. PubMed ID: 19429730 [TBL] [Abstract][Full Text] [Related]
2. Feasibility of using guidelines to choose treatment for prostate cancer. Mohan R; Beydoun H; Davis J; Lance R; Schellhammer P Can J Urol; 2010 Feb; 17(1):4975-84. PubMed ID: 20156376 [TBL] [Abstract][Full Text] [Related]
3. Patients' Survival Expectations With and Without Their Chosen Treatment for Prostate Cancer. Xu J; Janisse J; Ruterbusch JJ; Ager J; Liu J; Holmes-Rovner M; Schwartz KL Ann Fam Med; 2016 May; 14(3):208-14. PubMed ID: 27184990 [TBL] [Abstract][Full Text] [Related]
5. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423 [TBL] [Abstract][Full Text] [Related]
6. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow. Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849 [TBL] [Abstract][Full Text] [Related]
7. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era. Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899 [TBL] [Abstract][Full Text] [Related]
8. Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis. Lester-Coll NH; Goldhaber SZ; Sher DJ; D'Amico AV Cancer; 2013 May; 119(10):1808-15. PubMed ID: 23400678 [TBL] [Abstract][Full Text] [Related]
9. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. Adolfsson J; Steineck G; Hedlund PO Urology; 1997 Nov; 50(5):722-6. PubMed ID: 9372882 [TBL] [Abstract][Full Text] [Related]
11. Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinic. Lintz K; Moynihan C; Steginga S; Norman A; Eeles R; Huddart R; Dearnaley D; Watson M Psychooncology; 2003 Dec; 12(8):769-83. PubMed ID: 14681951 [TBL] [Abstract][Full Text] [Related]
12. Should we treat localized prostate cancer? An opinion. Menon M; Parulkar BG; Baker S Urology; 1995 Nov; 46(5):607-16. PubMed ID: 7495109 [TBL] [Abstract][Full Text] [Related]
13. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379 [TBL] [Abstract][Full Text] [Related]
14. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity. Adolfsson J; Tribukait B; Levitt S Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883 [TBL] [Abstract][Full Text] [Related]
15. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. Kibel AS; Ciezki JP; Klein EA; Reddy CA; Lubahn JD; Haslag-Minoff J; Deasy JO; Michalski JM; Kallogjeri D; Piccirillo JF; Rabah DM; Yu C; Kattan MW; Stephenson AJ J Urol; 2012 Apr; 187(4):1259-65. PubMed ID: 22335870 [TBL] [Abstract][Full Text] [Related]
16. Results of conservative management of clinically localized prostate cancer. Chodak GW; Thisted RA; Gerber GS; Johansson JE; Adolfsson J; Jones GW; Chisholm GD; Moskovitz B; Livne PM; Warner J N Engl J Med; 1994 Jan; 330(4):242-8. PubMed ID: 8272085 [TBL] [Abstract][Full Text] [Related]
17. The impact of socioeconomic status on prostate cancer treatment and survival in the southern Netherlands. Aarts MJ; Koldewijn EL; Poortmans PM; Coebergh JW; Louwman M Urology; 2013 Mar; 81(3):593-9. PubMed ID: 23312891 [TBL] [Abstract][Full Text] [Related]
18. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735 [TBL] [Abstract][Full Text] [Related]
19. [Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma]. Recker F Schweiz Med Wochenschr; 1996 Nov; 126(44):1881-90. PubMed ID: 8984601 [TBL] [Abstract][Full Text] [Related]
20. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer. Aizer AA; Chen MH; Hattangadi J; D'Amico AV BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]